Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489187 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1L3MBTL1MAPTRAB9A | |
| SCHEMBL6822506 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1L3MBTL1MAPTRAB9A | |
| SCHEMBL9518987 | 0.95 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1L3MBTL1MAPTTDP1 | |
| SCHEMBL6484891 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1L3MBTL1MAPTRAB9A | |
| SCHEMBL5525560 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1L3MBTL1MAPTRAB9A | |
| SCHEMBL5525558 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1L3MBTL1MAPTRAB9A | |
| SCHEMBL11546167 | 0.86 | SCN9A (0.44) | SMN1; SMN2MAPTRAB9ATSHRNPC1 | |
| SCHEMBL11546171 | 0.86 | SCN9A (0.44) | SMN1; SMN2MAPTRAB9ATSHRNPC1 | |
| SCHEMBL11541317 | 0.85 | MAPT (0.54) | SMN1; SMN2ALDH1A1MAPTRAB9ATSHR | |
| SCHEMBL11541320 | 0.85 | MAPT (0.54) | SMN1; SMN2ALDH1A1MAPTRAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867218-B2 | Compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2005-03-15 | — | — | US | disclosed |
| US-20030195200-A1 | Compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-10-16 | — | — | US | disclosed |
| US-6555577-B1 | For treatment and/or prevention of conditions mediated by the Peroxisome Proliferator-Activated Receptors (PPAR), such as diabetes and/or obesity; 3-(4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl)-2-butoxy-propionic acid for example | NOVO NORDISK A/S (DE) | 2003-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195200-A1 | Compounds, their preparation and use | PPARG, PPARA, PPARD | SMN1; SMN2 3127/4885ALDH1A1 257/4885L3MBTL1 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.